Hints and tips:
Related Special Reports
...A number of large pharmaceuticals groups are looking for ways to replenish their pipelines before they lose exclusivity on blockbuster drugs....
...James Keyte, director of the Fordham Competition Law Institute, also points to Khan’s longer-term aims....
...James Cavoli, a lawyer representing Passi, said they were pleased the DoJ had agreed not to pursue a criminal conviction....
...Chris Meekins, analyst at Raymond James & Associates, said Merck was the first but probably not the last big drugmaker that would challenge the government....
...Brewer’s unexpected exit comes within five weeks of WBA’s announcement that its chief financial officer, James Kehoe, would be leaving....
...For the GSK legal team, this meant recasting itself to support a smaller, more focused pharmaceutical business....
...Analysts have been predicting a boom in mergers and acquisitions in the pharmaceutical sector as valuations have come down in the worst biotech sell-off since the early 2000s....
...The deal comes when the valuation of biotech stocks has dropped sharply, making acquisition targets in the sector more attractive to large pharmaceutical companies....
...The US-based pharmaceutical group said on Tuesday it would pay $380 for each outstanding Abiomed share in a move the company hopes will help its broader effort to focus on drugs and medical devices....
Setback for FTC after administrative law judge gives nod to acquisition of cancer testing group
...Pfizer in May agreed a $11.6bn deal to buy US biotech Biohaven Pharmaceuticals, which is developing migraine treatments....
Investors push for higher price or spin-off after rejecting Unilever’s £50bn offer
...Merck’s cancer immunotherapy Keytruda is a wonder drug that has transformed not just the survival odds of thousands of patients but also the pharmaceutical company’s fortunes....
...His follow-up nominations were for Children of a Lesser God, in 1986, and James L Brooks’s Broadcast News in 1987....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...In June, the president created a task force to deal with supply chain troubles in areas ranging from semiconductors to rare earths and pharmaceutical ingredients....
Elderly and at-risk to be offered third dose of BioNTech/Pfizer Covid-19 jab under scaled-back plan
Concerns raised that vaccine sites and freight services will struggle during rollout of third jabs
New deal for Covid vaccinations comes amid debate over whether Delta variant requires third doses
...It is the largest settlement James has secured during her tenure as New York attorney-general, which began in 2019. Additional reporting by Hannah Kuchler in London...
...“These companies continued to profit off the misery, death and destruction nationwide and today we put an end to it,” said Letitia James, New York attorney-general....
...James added that the pharmaceutical company’s heavy marketing of opioids was partially motivated by quotas for sales staff....
...Additional reporting by James Politi in Washington...
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The western pharmaceutical companies that produce coronavirus vaccines are at various stages of carrying out trials of their shots on children, some as young as six months, although Pfizer and BioNTech are...
International Edition